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Angiogenesis is the process by which new blood vessels form from existing vessel networks. In the past three decades, signiﬁcant
progress has been made in our understanding of angiogenesis; progress driven in large part by the increasing realization that
blood vessel growth can promote or facilitate disease. By the early 1990s, it had become clear that the recently discovered “vascular
endothelial growth factor” (VEGF) was a powerful mediator of angiogenesis. As a result, several groups targeted this molecule
as a potential mediator of retinal ischemia-induced neovascularization in disorders such as diabetic retinopathy and retinal vein
occlusion. Around this time, it also became clear that increased intraocular VEGF production was not limited to ischemic retinal
diseases but was also a feature of choroidal vascular diseases such as neovascular age-related macular degeneration (AMD). Thus,
a new therapeutic era emerged, utilizing VEGF blockade for the management of chorioretinal diseases characterized by vascular
hyperpermeability and/or neovascularization. In this review, we provide a guide for clinicians on the development of anti-VEGF
therapies for intraocular use.
1.Introduction
In 1948, Isaac Michaelson proposed that a diﬀusible factor
(named afterward “factor X”) could be responsible, not
only for the development of the normal retinal vasculature
but also for pathological neovascularization in prolifera-
tive diabetic retinopathy and other ocular disorders [1].
By the early 1990s, it had become clear that the recently
discovered “vascular endothelial growth factor” (VEGF)
possessed many of the requisite characteristics of a “factor
X” [2]. As a result, several groups targeted this molecule
as a potential mediator of retinal ischemia-induced neovas-
cularization in disorders such as diabetic retinopathy and
retinal vein occlusion (RVO) [3, 4]. Around this time, it also
became clear that increased intraocular VEGF production
was not limited to ischemic retinal diseases but was also a
feature of choroidal vascular diseases such as neovascular
age-related macular degeneration (AMD) [5, 6]. Thus, a
new therapeutic era emerged, utilizing VEGF blockade for
the management of chorioretinal diseases characterized by
vascular hyperpermeability and/or neovascularization.
In this review, we begin by providing an overview of
angiogenesis, the manner in which VEGF was discovered to
be central to this process, and then a summary of VEGF
biology. In this manner, we aim to provide the clinician with
an understanding of the clinical scenarios in which VEGF
blockade is likely to be successful and of patient beneﬁt. We
continue by describing the development of four key anti-
VEGF therapies (pegaptanib, bevacizumab, ranibizumab,
and aﬂibercept) and the results of their application in a
selection of pioneering clinical trials. By describing the main
features of their development in a manner accessible to clin-
icians, we aim to highlight those molecular characteristics,
of each agent, with implications for clinical outcomes and
patient safety. We conclude the review by describing likely
future directions in the application of anti-VEGF therapy in
chorioretinal disease.2 Journal of Ophthalmology
2. Angiogenesis
2.1. Overview. Angiogenesis is the process by which new
blood vessels form from existing vessel networks (by com-
parison, vasculogenesis is a form of de novo blood vessel
formation that is typically seen in the embryo) [7–9].
Angiogenesisbeginswithvasodilatationandincreasesinvas-
cular permeability, followed by activation and proliferation
of vascular endothelial cells; these changes are accompa-
nied by degradation of the surrounding extracellular matrix
(ECM), facilitating endothelial cell migration. The migrat-
ing endothelial cells assemble, form cords, and ultimately
acquirelumens;furtherdiﬀerentiationtoaccommodatelocal
requirements then occurs and a network of similarly dif-
ferentiated periendothelial cells and matrix develops. After
further remodeling a complex vascular network is ultimately
formed.
2.2. Role of Angiogenesis in Disease. In the past three decades,
signiﬁcant progress has been made in our understanding of
angiogenesis: progress driven in large part by the increasing
realization that blood vessel growth can promote or facilitate
disease [10]. This major conceptual advance ﬁrst occurred
in the 1930s and 1940s, when it was hypothesized that
induction of blood vessel growth through release of vasopro-
liferative factors would confer a growth advantage on tumor
cells [11]. Subsequently, in the 1970s, Folkman hypothesized
that blockade of angiogenesis could be a strategy to treat
cancerandotherdisorders[12]. However,adoption of sucha
strategy ﬁrst required the identiﬁcation and characterization
of the mediators of angiogenesis—a major technological
challenge at that point.
2.3. Putative Regulators of Angiogenesis. In the subsequent
years, advances in molecular biology led to the identiﬁca-
tion of many putative regulators of angiogenesis, with well-
known examples including basic ﬁbroblast growth factor
(bFGF), transforming growth factor (TGF)-β, and the
angiopoietins [7]. In the 1980s, bFGF was thought to be the
major angiogenic factor in the pituitary and other organs.
However, this model was called into question when, in
1986, it became clear that bFGF lacks a peptide sequence
necessary for secretion and is thus conﬁned intracellularly
(angiogenesis is a process that requires diﬀusion in an
extracellular environment) [13].
2.4. Discovery of VEGF. In the mid-1980s, Ferrara and Hen-
zel cultured a population of nonhormone secreting follicular
cells—with unusual characteristics—from bovine pituitary
glands (follicular cells have cytoplasmic projections that
establish intimate connections with perivascular spaces and
were thought to have a role in regulating growth and main-
tenance of pituitary vasculature) [14]. Ferrara discovered
that culture medium conditioned by these cells strongly
promoted endothelial cell growth. He hypothesized that this
mitogenic activity may be the result of a secreted protein;
the subsequent isolation and sequencing of this protein led
to discovery of the most important mediator of angiogenesis
currently known—VEGF [15].
2.5. Vascular Permeability Factor. Independently, in the early
1980s, Senger et al. had reported the identiﬁcation of a per-
meability-enhancing protein (in the supernatant of a guinea
pig tumor cell line), which they named “vascular permeabil-
ity factor” (VPF) [16]. In 1989, at the same time Ferrara
and coworkers were reported their discovery of VEGF. Keck
et al. reported the isolation and sequencing of VPF [17].
Surprisingly, their ﬁndings indicated that VEGF and VPF
were, in fact, the same molecule.
2.6. Clinical Role for VEGF Blockade. Although multiple
growth factors other than VEGF have been implicated in
the angiogenic process (e.g., bFGF), VEGF appears critical
for a number of reasons: its production is driven by hyp-
oxia; it is highly selective for endothelial cells, it possesses
diﬀusion characteristics that allow it to reach its target,
and it aﬀects multiple aspects of the angiogenic process
[18, 19]. VEGF also causes vascular dilatation and promotes
vasopermeability,bothofwhichfacilitatearichenvironment
for the growth of new vessels. Thus, despite the complexity
of the angiogenic process, and the potential redundancy of
the growth factors involved, VEGF blockade was quickly
recognized as a promising approach for the restriction of
blood vessel formation in a variety of pathologic scenarios
[8].
3.VEGFBiology
3.1. Gene Family. VEGF-A, ﬁrst discovered in 1989 (see
above), is the prototype member of a gene family (i.e.,
a group of genes with shared sequences and with similar
biochemical functions) that also includes placental growth
factor (PLGF), VEGF-B, VEGF-C, VEGF-D, and VEGF-E
(prior to the discovery of other family members, VEGF-A
was known simply as VEGF; the terms are used interchange-
ably in this review) [10, 18]. Of note, VEGF-C and VEGF-
D are involved in the regulation of lymphatic angiogenesis
[20], demonstrating the unique role of this gene family in
controlling multiple structural components of the vascular
system.
3.2. Regulation of VEGF Gene Expression. Oxygen tension
has a key role in regulating the production of VEGF. VEGF
mRNA expression is induced by exposure to low oxygen
tension under a variety of pathophysiological circumstances,
and it is now well established that a transcription factor,
hypoxia-inducible factor-1 (HIF-1), is a key mediator of this
response [21, 22]. Recent studies have also shown that Von
Hippel Lindau (VHL) protein, a product of the VHL tumor
suppressor gene, provides negative regulation of VEGF and
otherhypoxia-induciblegenes(inactivationofthisgeneleads
to development of capillary hemangioblastomas in the retina
and cerebellum, and in many cases, renal cell carcinomas)
[23].
Several major growth factors, such as epidermal growth
factor, also upregulate VEGF mRNA expression, suggesting
that paracrine or autocrine release of such factors works
in concert with local hypoxia to increase production of
VEGF [24, 25]. In addition, inﬂammatory cytokines, such asJournal of Ophthalmology 3
interleukin-1αandinterleukin-6,induceexpressionofVEGF
in several cell types (an observation in agreement with the
hypothesis that VEGF plays a role in the angiogenesis and
hyperpermeability seen in some inﬂammatory disorders)
[25].
3.3. VEGF Isoforms. The human VEGFA gene is organized as
eight exons separated by seven introns (i.e., eight expressed
regions that are joined together in the ﬁnal mature RNA)
[26]. Alternative splicing of the VEGFA gene results in
the generation of four major isoforms (VEGF121,V E G F 165,
VEGF189, and VEGF206), having, respectively 121, 165, 189,
and 206 amino acids. VEGF165 is the predominant isoform
[27].
Native VEGF is a heparin-binding glycoprotein (heparin
is commonly used during protein puriﬁcation due to its
structural similarity to RNA and DNA), with a protein
molecular weight of 45kDa, the properties of which corre-
spond closely to those of VEGF165 [27]. Loss of the heparin-
binding domain of VEGF results in a signiﬁcant loss in
its mitogenic activity [28]. VEGF121, while freely diﬀusible
in the ECM, is acidic and does not bind heparin [27].
Conversely, VEGF189 and VEGF206, while being highly basic
and capable of binding heparin with high aﬃnity, are almost
completely sequestered in the ECM. Thus, VEGF165,w i t h
intermediary properties, possesses the optimal characteris-
tics of bioavailability and biological potency [27].
3.4. VEGF Receptors. VEGF binds to two, related, receptor
tyrosine kinases: VEGF Receptor 1 (VEGFR1) and VEGF
Receptor 2 (VEGFR2) [27]. Both VEGFR1 and VEGFR2
have seven immunoglobulin-like domains in the ECM, a
singletransmembraneregion,andatyrosinekinasesequence
interruptedbyakinase-insertdomain.In1992,VEGFR1was
the ﬁrst VEGF receptor discovered and was found to bind
VEGF with high aﬃnity [29]. However, despite its lower
binding aﬃnity for VEGF relative to VEGFR1, there is now
agreement that VEGFR2 is the major mediator of the mito-
genic, angiogenic, and permeability-enhancing eﬀects of
VEGF (the precise function of VEGFR1 is still under debate
but may provide a “decoy eﬀect” on VEGF signaling) [27]. In
addition, VEGF interacts with a family of nonsignaling core-
ceptors, the neuropilins—neuropilin-1 (NRP-1) appears to
presentVEGF165 toVEGFR2inaconﬁgurationthatincreases
the eﬀectiveness of VEGFR2-mediated signal transduction
[18, 30].
3.5. Activities of VEGF. Vascular endothelial cells are the
primary targets for VEGF biologic activity, with their mito-
genic eﬀects well documented, both in vitro and in vivo [27].
In particular VEGF induces a potent angiogenic eﬀect in a
variety of animal models in vivo [15, 31].
VEGF also acts as a survival factor for endothelial cells
in a variety of circumstances. Inhibition of VEGF results in
extensive apoptotic changes in the vasculature of neonatal,
but not adult mice [32]; furthermore, a marked VEGF de-
pendence has been demonstrated in the endothelial cells of
newly formed but not of established vessels within tumors
[33]. Coverage by pericytes is thought to be one of the key
events, resulting in loss of VEGF dependence [34].
VEGF has also been shown to act as a chemotactic agent
for bone marrow-derived monocytes [35], a pro-inﬂam-
matory cytokine through upregulation of intercellular adhe-
sion molecule-1 (ICAM-1) with consequent leukocyte adhe-
sion [36], and a promoter of blood vessel extravasation
through the upregulation of matrix metalloproteinases and
decreased release of metalloproteinase inhibitors [37].
The eﬀects of VEGF on the promotion of vascular leak-
age, both in inﬂammation and in other pathologic circum-
stances, are also well established (prior to its isolation and
sequencing, VEGF was initially characterized as “vascular
permeability factor” by Senger et al. (see above)) [16]. Con-
sistent with this role, VEGF has been shown to promote
dissolutionoftightjunctionsbetweenendothelialcellsandto
induce endothelial fenestration in a number of vascular beds
[38]. VEGF also induces vasodilatation in a dose-dependent
fashion as a result of release of endothelial cell-derived nitric
oxide—systemic blockade of VEGF may thus result in a
clinically signiﬁcant adverse hypertensive eﬀect [39].
Taken together, blockade of the biologic eﬀects of VEGF
resultsinrapidvesselremodelingwithregressionofpericyte-
poor capillaries, reductions in vascular lumen diameter, and
reductions in vascular permeability [33, 34]. More recently,
evidence has suggested that VEGF could have additional
neuroprotective eﬀects [40].
3.6. Role of VEGF in Ocular Disease. In 1994, Aiello et al.
found a striking correlation between intraocular VEGF con-
centrations and active proliferative retinopathy in patients
with diabetes and ischemic central retinal vein occlusion
(CRVO) [3]. Around the same time, Adamis et al. reported
increased concentrations of VEGF in the vitreous of patients
with diabetic retinopathy [4]. In 1996, it also became clear
that increased intraocular levels of VEGF were not limited to
ischemic retinal disorders: in a pair of inﬂuential studies, the
localization of VEGF to choroidal neovascular membranes
in patients with neovascular AMD was reported [5, 6].
Proof-of-concept studies then demonstrated that blockade
of VEGF, in animal models, led to marked decreases in
retinal and iris neovascularization [41, 42]. Furthermore,
exogenous administration of VEGF was demonstrated to
produce retinal ischemia and vascular hyperpermeability in
primates [43].
4.Pegaptanib
Pegaptanib sodium is an RNA aptamer that binds to the
heparin-binding domain of VEGF and, thus, prevents the
predominantVEGF165 isoformfrombindingtoVEGFrecep-
tors [44]. Pegaptanib was licensed to EyeTech Pharmaceuti-
cals (now OSI Pharmaceuticals) for late stage development
and marketing in the United States as “Macugen” (outside
the USA, pegaptanib is marketed by Pﬁzer Inc.).
4.1. Chemistry. Aptamers (from the Latin aptus, to ﬁt, and
the Greek meros, part or region) are oligonucleotides that
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by selection from a large random sequence pool [45]. In
this manner, aptamers are commonly used for basic research
and clinical purposes as macromolecular drugs. Aptamers
constitute one of four classes of oligonucleotide reagents,
the others being antisense oligonucleotides, ribozymes, and
small interfering RNAs (siRNAs) [44]. However, in contrast
with these other entities, aptamers can act on extracellular
targets and, therefore, are not required to cross cell mem-
branes to exert their therapeutic eﬀects.
The selection of aptamers has become relatively straight-
forward with the advent of “systematic evolution of ligands
by exponential enrichment” (SELEX) [46]; in this process,
aptamers are engineered to bind to various target molecules
through repeated rounds of in vitro selection. Aptamers
oﬀer molecular recognition properties that rival that of
antibodies, but with a number of advantages: (1) they can be
engineered completely in vitro, (2) they are readily produced
by chemical synthesis, (3) they possess desirable storage
properties, and (4) they elicit little or no immunogenicity
[44, 45]. Pegaptanib has the distinction of being the ﬁrst
aptamer therapeutic approved for use in humans [44].
Having chosen VEGF165 as the target for selection of
a prospective anti-VEGF aptamer, three separate iterations
of the SELEX methodology were carried out by scientists
at NeXstar Pharmaceuticals [44]. By 1998, three, stable,
high-aﬃnity anti-VEGF165 aptamers had been characterized,
one of which was selected for development as pegaptanib
(initially designated NX1838, and then, EYE001) (all three
aptamers demonstrated little or no binding to VEGF121)
[47].
4.2. Preclinical Studies. The fact that pegaptanib oﬀers se-
lective inhibition of a single isoform oﬀers the theoretical
advantage that “normal” vessels may be maintained by
VEGF121 and other isoforms, while pathologic neovascular-
ization may be suppressed [18, 44, 48]. Indeed, prior to
clinical trials in humans, basic research demonstrated that
administration of EYE001 (pegaptanib) could lead to both
reduced vascular permeability and inhibition of both corneal
and retinal neovascularization [49]. It has subsequently been
shown, however, that various proteases activated during
angiogenesis may cleave VEGF165 (and longer isoforms) to
generate nonheparin binding fragments—such fragments
may be suﬃcient to drive angiogenesis while evading pegap-
tanib blockade [50, 51].
4.3.PharmacokineticsandMetabolism. Nonmodiﬁedaptam-
ers are rapidly cleared from the body, with a half-life of mi-
nutes to hours, as a result of nuclease degradation and renal
clearance (a result of the inherently low molecular weight
of aptamers). Therefore, modiﬁcation of aptamers, such as
2 -ﬂuorine-substituted pyrimidines, and polyethylene glycol
(PEG) linkage, can be used to increase their stability and
terminal half-life (both approaches are used in the case of
pegaptanib) [44]. Using these approaches pegaptanib has
been found to be stable in human plasma, at ambient tem-
peratures, for more than 18 hours [52].
Pegaptanib pharmacokinetics have been evaluated fol-
lowing intravitreal injection in monkeys and rabbits [49,
52, 53]. In both animal models, pegaptanib was detected in
the vitreous at biologically active levels for at least 28 days
following a single 0.5mg intravitreal injection. In rabbits,
after a single dose of pegaptanib, the initial vitreous humor
levels were approximately 350μg/mL and decreased by an
apparent ﬁrst-order elimination process to approximately
1.7μg/mL by day 28. By comparison, the plasma concentra-
tions of pegaptanib were signiﬁcantly lower, ranging from
0.092μg/mL to 0.005μg/mL (day 1 to day 21). Plasma levels
also declined by an apparent ﬁrst-order elimination. In a
human pharmacokinetic study, pegaptanib was not found
to accumulate in the plasma after multiple doses (i.e.,
systemic exposures were similar at diﬀerent time-points);
furthermore, no antipegaptanib antibodies (IgG or IgM)
were detected [54].
4.4. Selected Clinical Studies: Neovascular AMD. In 2004, fol-
lowing publication of results from two, concurrent, phase
III clinical trials (the VEGF Inhibition Study in Ocular Neo-
vascularization, or VISION, trials), pegaptanib was licensed
for use in the USA by the Food and Drug Administration
(FDA) [55]. The VISION trials—two large-scale, multicen-
ter, randomized, controlled, clinical trials—demonstrated
that intravitreal administration of 0.3mg of pegaptanib at
six weekly intervals, for a period of 48 weeks (a total of nine
treatments), was eﬀective in reducing moderate vision loss
in patients with neovascular AMD (higher doses were not
shown to provide clinical beneﬁt). In these studies, 70% of
pegaptanib-treated patients avoided further moderate visual
loss (deﬁned in most AMD studies as a loss of fewer than 15
letters of visual acuity) compared with 55% of sham-treated
patients. However, treated eyes still lost, on average, 1.5
lines of visual acuity over the course of a year of treatment.
There was no evidence of either systemic toxicity or an
increased risk of potential VEGF inhibition-related adverse
events (a safety proﬁle conﬁrmed following three years of
treatment/follow-up) [56].
4.5. Selected Clinical Studies: Diabetic Macular Edema. In
2011, the results of a phase II/III-randomized controlled
trial, of intravitreal pegaptanib for the treatment of diabetic
macular edema (DME), were published [57]. In this study,
subjects with DME received injections of 0.3mg of intravit-
realpegaptanib,orshaminjections,everysixweeksforayear,
and then according to prespeciﬁed criteria in a second year.
In all, 36.8% of patients receiving pegaptanib, versus 19.7%
of those in the sham group, experienced an improvement
in visual acuity greater than 10 letters when compared to
baseline. After two years, pegaptanib-treated patients gained,
on average, 6.1 letters of visual acuity (versus 1.3 letters
for controls). Pegaptanib-treated patients also received fewer
focal/grid laser treatments (subjects were eligible for this
beginning at week 18).
5.Bevacizumab
Bevacizumab(Avastin,Genentech,SouthSanFrancisco,CA)
is a full-length monoclonal antibody, ﬁrst derived from a
murine source and prepared for intravenous administration,Journal of Ophthalmology 5
which binds to and inhibits all isoforms of VEGF [18, 58].
Bevacizumab was originally developed and approved for the
treatment of metastatic colorectal cancer but may also be
of beneﬁt in the treatment of nonsmall cell lung cancer,
metastatic breast cancer, and glioblastoma multiforme [59].
Use of bevacizumab in these contexts has been associated
with increased incidences of hypertension, bleeding, and
thromboembolic events [59]. However the doses employed
for intraocular use are many times lower than those used
systemically, and the eﬃcacy and safety of bevacizumab,
for the treatment of neovascular AMD, has recently been
demonstrated in phase III clinical trials [60, 61].
5.1. Chemistry. Bevacizumab was originally developed from
a mouse antihuman VEGF antibody (A.4.6.1), generated
from mice immunized with the VEGF165 isoform [58].
A.4.6.1 recognizes all isoforms of VEGF and, in 1992, was
shown to inhibit growth of human tumor cell lines in
vivo [62]. Subsequently, in 1996, intraocular administration
of A.4.6.1 was found to inhibit iris neovascularization
occurring secondary to retinal ischaemia in a primate model
[42]. In 1997, bevacizumab was developed by humaniza-
tion of A.4.6.1 [63]. In this process, six complementarity-
determining regions (CDRs) (i.e., regions that determine
antibody-binding) were transferred from A.4.6.1 to a human
antibody framework previously used for humanizations.
However, this transfer reduced VEGF binding over 1000
fold—to reduce this eﬀect, eight framework residues were
changed from human to murine.
Bevacizumab is produced in Chinese hamster ovary cells
usingexpressionplasmids(plasmidsareDNAmoleculessep-
arate from chromosomal DNA that can be used to manu-
facture large quantities of proteins) [58]. Bevacizumab is a
149kDa full-length antibody, composed of two light chains
and two heavy chains, and with a 93% human amino acid
sequence.
5.2.PreclinicalStudies. Theeﬀectsofbevacizumabhavebeen
examined in a number of in vitro and in vivo studies [58];
as bevacizumab was not developed with the intention of
intraocular administration, many of these studies were per-
formed only after its widespread adoption in this manner for
clinical practice. In both murine and porcine models, beva-
cizumab has been demonstrated to reduce VEGF-induced
permeability and proliferation of choroidal endothelial cells
and to inhibit VEGF-induced migration of human umbilical
vein endothelial cells [64–66]. In addition, bevacizumab has
been demonstrated as nontoxic, or not to alter the viability
of, neurosensory retinal cells, retinal ganglion cells, and
humanretinalpigmentepithelium(RPE)cells[58].Concern
has also been raised about the Fc component present in
full-length antibodies such as bevacizumab—Fc domains
are known to initiate complement activation and immune
cell destruction [18]. Recent studies have demonstrated that
choroidal neovascular membranes from patients with neo-
vascularAMDtreatedwithbevacizumabarecharacterizedby
signiﬁcantly higher inﬂammatory activity [67]. Preliminary
resultshavealsodemonstratedthatbevacizumabFcdomains
are capable of binding eﬀectively to human RPE and human
umbilical vascular endothelial cell (HUVEC) membranes via
Fc receptors, activating the complement cascade and leading
to cell death [58].
5.3. Pharmacokinetics and Metabolism. Bevacizumab was
developed for intravenous administration in diseases such as
colorectalcancer[59].As aresult,compounding into smaller
dosesisrequiredforintraocularadministration.Studieshave
demonstrated diﬀerences in bevacizumab concentration and
the presence of particulate contaminants following this pro-
cess, emphasizing the need for implementation of optimal
protocols when compounding pharmacies prepare this drug
for intravitreal use [58, 68].
The pharmacokinetics of bevacizumab, following intrav-
itreal administration, have not been well characterized.
Knowledge of the vitreous half-life is an important consid-
eration when optimizing retreatment frequencies, whereas
serum concentrations are an important factor with respect
to systemic adverse eﬀects (e.g., stroke). In rabbits receiving
1.25mg of bevacizumab, the vitreous half-life was 4.32 days
(versus2.88daysforranibizumab),andthemaximumserum
concentrations were reached after eight days [69, 70]. Small
amountsofbevacizumabwerealsodetectedinthevitreousof
the fellow, uninjected eye. In a more recent study performed
in humans, an aqueous half-life of 9.82 days was found after
intravitreal injection of 1.5mg of bevacizumab [71].
The retinal penetration of bevacizumab has also been
studied in animal models (experience with retinal pene-
tration of other, full-length antibodies suggested that their
large size would act as a limiting factor). In rabbits, Shahar
et al. demonstrated, using confocal immunohistochemistry,
that full thickness retinal penetration occurred 24 hours
after intravitreal injection; this study also demonstrated the
essential absence of bevacizumab from the retina by four
weeks post injection [72].
5.4. Selected Clinical Studies: Neovascular AMD. In 2010, the
results of the ABC (Avastin (Bevacizumab) for treatment
of Choroidal Neovascularization) trial provided the ﬁrst
evidence from a phase III-randomized controlled study
for the eﬃcacy of intravitreal bevacizumab in neovascular
AMD [60, 73]. In this single year trial, 32% of patients
treated with bevacizumab gained 15 or more letters from
baseline visual acuity (initial three month loading phase, and
then retreatment as required). In addition, 91% of patients
receiving bevacizumab lost fewer than 15 letters of visual
acuity from baseline, and mean visual acuity increased by 7.0
letters over the study period.
In 2011, the results of the CATT (Comparison of Age-
Related Macular Degeneration Treatments Trials) study pro-
vided further evidence, from larger phase III trial, for the
eﬃcacy of bevacizumab in neovascular AMD [61]. In this
trial, 31.3% of patients treated with bevacizumab on a ﬁxed,
monthly regimen gained 15 or more letters from baseline
visual acuity (28.0% for patients treated with bevacizum-
ab as required). In addition, 94.0% of patients receiving
bevacizumab on a ﬁxed, monthly regimen lost fewer than
15 letters of visual acuity from baseline (91.5% in the
bevacizumab as required group). Finally, mean visual acuity6 Journal of Ophthalmology
increased by 8.0 letters over the study period in those re-
ceiving bevacizumab monthly (5.9 letters in bevacizumab as
required group). Of note, statistical comparisons between
bevacizumab given as needed, and given on a ﬁxed, monthly
regimen, were inconclusive.
6.Ranibizumab
Ranibizumab(formerlyknownasrhuFAbV2)isanantibody
fragment that binds and inhibits all isoforms of VEGF
[18]. Speciﬁc development of ranibizumab for intraocular
use was driven, in part, by preliminary studies suggesting
that full-length monoclonal antibodies would not distribute
across all retinal layers [74]. Furthermore, the relatively
long systemic half-life of full-length antibodies (versus an-
tibody fragments) raised concerns about systemic toxicity in
patients requiring long-term anti-VEGF blockade [18].
6.1. Chemistry. Bevacizumab is constructed from A.4.6.1
using one of 12 possible Fab (fragment antigen binding)
variants: “Fab 12” [58]. Ranibizumab is constructed using
ad i ﬀerent Fab variant from A.4.6.1: “Fab MB1.6”, in an
eﬀort to obtain higher binding aﬃnities for VEGF [75].
Ranibizumab is produced as a 48kDa antibody fragment,
in E. coli, using expression plasmids [58]. It is a chimeric
molecule, consisting of an antigen-binding murine compo-
nent, and a nonbinding human component that serves to
makeitlessantigenic(inGreekmythology,thechimerawasa
monsterwithalion’shead,agoat’sbody,andaserpent’stail).
On a molar basis, ranibizumab is between ﬁve- and 20-times
more potent than bevacizumab at binding of VEGF [75].
6.2. Preclinical Studies. Preclinical studies have demonstrat-
ed the safety, tolerability, and eﬃcacy of ranibizumab in an-
imal models. In particular, intravitreal administration of
ranibizumab reduced vascular leakage in a monkey model
of choroidal neovascularization (CNV), while pretreatment
with ranibizumab prevented laser-induced development of
CNV in this model [76].
6.3. Pharmacokinetics and Metabolism. The pharmacokinet-
ics of ranibizumab, after intravitreal administration, have
been studied both in animal models and in human trials [69,
77, 78]. Ranibizumab is thought to exit the vitreous cavity
posterior via retinal penetration and choroidal vascular
drainage or anteriorly via the aqueous drainage route. In
animal studies, ranibizumab is cleared from the vitreous
with a half-life of approximately three days [69]. Therefore,
ranibizumabisthoughttomaintainbiologicallyactiveretinal
concentrations for approximately one month. After reaching
a maximum at approximately one day, the serum concen-
tration of ranibizumab declines in parallel with this. In
human studies, following monthly intravitreal ranibizumab
administration, maximum serum concentrations were dose
dependent but low (0.3ng/mL to 2.36ng/mL—levels more
than 1000 fold lower than in the vitreous and thought to be
below the concentrations necessary for reduction in biolog-
ical activity of VEGF by 50%) (http://www.gene.com/). In a
recent study by Bakri et al., no ranibizumab was detected in
the serum, or the fellow uninjected eye, of rabbits injected
with 0.5mg of intravitreal ranibizumab; by comparison,
small amounts of bevacizumab were detected, both in the
serum and in the fellow-uninjected eye [69].
6.4. Selected Clinical Studies: Neovascular AMD. In 2006,
ranibizumab was licensed for use in the United States fol-
lowing publication of the MARINA and ANCHOR studies
[79, 80].
In the MARINA (Minimally Classic/Occult Trial of the
Anti-VEGF Antibody Ranibizumab in the Treatment of Ne-
ovascular AMD) trial, patients with either “minimally clas-
sic” or “occult” angiographic leakage patterns were random-
izedtoreceivemonthlyinjectionsofintravitrealranibizumab
(0.3mg or 0.5mg) or monthly sham injections [80]. At the
12-month point of this study, visual acuity had improved by
15ormorelettersin33.8%ofthe0.5mggroup(ascompared
with only 5.0% of the sham-injection group). Furthermore,
patients receiving ranibizumab, on average, demonstrated
increases in visual acuity (7.2 letters in the 0.5mg group),
while those receiving sham therapy, on average, demon-
strated losses (10.4 letters in the sham-injection group). In
addition, the vast majority of patients receiving ranibizumab
avoided moderate visual loss (94.6% of those receiving
0.5mg), while only 62.2% of the control group managed to
do so.
In the ANCHOR (Anti-VEGF Antibody for the Treat-
ment of Predominantly Classic Choroidal Neovasculariza-
tion in AMD) trial, patients with “predominantly classic”
angiographic leakage patterns were randomized to receive
either 24 monthly intravitreal injections of ranibizumab
(either 0.3mg or 0.5mg) or photodynamic therapy with
verteporﬁn [79]. Visual acuity improved by 15 letters or
more in 40.3% of the 0.5mg group (as compared with 5.6%
of the verteporﬁn group). As in the MARINA trial, those
receiving ranibizumab also demonstrated a mean increase in
visual acuity (11.3 letters in the 0.5mg group), while those in
the control group experienced a mean decrease (9.5 letters
in the verteporﬁn group). Similarly, 96.4% of those given
0.5mg avoided further moderate visual loss (as compared
with 64.3% of those in the verteporﬁn group).
In the two-year HORIZON extension trial of the
MARINA and ANCHOR studies, 69% of patients still re-
quired further intravitreal injections—despite receiving
monthly injections for a two-year period prior to this. Fur-
thermore, the median visual gain at the conclusion of
MARINA and ANCHOR decreased with less frequent rani-
bizumab dosing in the HORIZON trial [81].
In the MARINA and ANCHOR trials, the incidence of
serious adverse eﬀects was similar between treatment and
control groups—for arterial thromboembolic events (e.g.,
nonfatal myocardial infarctions, nonfatal stroke, and death
from a vascular or unknown cause) were 3.8% (sham) versus
4.6% (0.5mg ranibizumab) in MARINA and 4.2% (PDT)
versus 5.0% (0.5mg ranibizumab) in ANCHOR. An interim
analysis from the SAILOR (Safety Assessment of Intravitreal
Lucentis for AMD) study showed a trend for an increase in
the incidence of stroke in the group treated with 0.5mg of
ranibizumab [82, 83]. Moreover, the incidence of stroke wasJournal of Ophthalmology 7
higher with preexisting risk factors, in particular a previous
history of stroke or arrhythmia. These ﬁndings, and recent
studies reporting an association between AMD itself and
higher risk of stroke, suggest that extra discussion of risk-
to-beneﬁt ratios may be warranted prior to ranibizumab
treatment in patients with a history of stroke [82, 84].
In 2011, the results of the CATT study conﬁrmed the eﬃ-
cacy of ranibizumab in the treatment of neovascular AMD
and allowed comparison of outcomes with bevacizumab
[61].Inthistrial,34.2%ofpatientstreatedwithranibizumab
on a ﬁxed, monthly regimen gained 15 or more letters
from baseline visual acuity (24.9% for patients treated with
ranibizumab as required). In addition, 94.4% of patients
receiving ranibizumab on a ﬁxed, monthly regimen lost
fewer than 15 letters of visual acuity from baseline (95.4%
in the ranibizumab as required group). Finally, mean visual
acuity increased by 8.5 letters over the study period in those
receiving ranibizumab monthly (6.8 letters in ranibizumab
as required group). No statistically signiﬁcant diﬀerence in
visual outcomes was found between ranibizumab admin-
istered monthly and bevacizumab administered monthly
(nor for either drug administered as required). Rates of
death, myocardial infarction, and stroke were also similar for
patients receiving either ranibizumab or bevacizumab.
6.5. Selected Clinical Studies: DME. The use of intravitreal
ranibizumab for the treatment of DME has recently been
evaluated in a number of phase III clinical trials, including
theDRCR(DiabeticRetinopathyClinicalResearch)Network
and RESTORE studies [85, 86]. In the DRCR Net trial, the
mean change in visual acuity from baseline, after one year,
was signiﬁcantly greater in those receiving ranibizumab (+9
letters in those receiving ranibizumab with deferred laser)
versus those receiving laser alone (+3 letters) [85]. Similarly,
in the RESTORE study, ranibizumab monotherapy resulted
in a greater mean change in visual acuity from baseline (+6.1
letters) versus laser monotherapy (+0.8 letters) [86]. In both
studies, ranibizumab therapy had a similar safety proﬁle for
the treatment of DME as has been previously described for
neovascular AMD.
6.6. Selected Clinical Studies: CRVO. Treatment of CRVO-
associated macular edema was evaluated in the phase III,
CRUISE (Central Retinal Vein OcclUsIon Study: Evaluation
of Eﬃcacy and Safety) trial [87]. The study was a 6-month,
multicenter, randomized, sham injection-controlled study,
with an additional 6 months of follow-up (total 12 months).
The study included a six-month treatment period, during
which subjects received monthly intraocular injections of
0.3mg or 0.5mg ranibizumab, or sham injections; and a
six-month observation period, during which all patients
could receive monthly ranibizumab retreatment if they met
prespeciﬁed functional and anatomic criteria.
Mean change from baseline visual acuity at month six
was +14.9 letters in the 0.5mg ranibizumab group and
+0.8 letters in the sham group. The percentage of patients
who gained ≥15 letters in visual acuity at month six were
47.7% in the 0.5mg ranibizumab and 16.9% in the sham
group. In addition, the safety proﬁle was consistent with
previous phase III clinical trials of ranibizumab for other
ocular disorders, and no new safety events were identiﬁed in
patients with CRVO.Treatmentwithranibizumab as needed,
during the six-month observation period, maintained the
visual beneﬁts gained in the initial treatment phase [88].
6.7. Selected Clinical Studies: Branch Retinal Vein Occlusion.
Treatment of branch retinal vein occlusion- (BRVO-) associ-
ated macular edema was evaluated in the phase III, BRAVO
(BRAnch Retinal Vein Occlusion: Evaluation of Eﬃcacy and
Safety) trial [89]. As with the CRUISE study, the BRAVO trial
was a 6-month, multicenter, randomized, sham injection-
controlled study, with an additional 6 months of follow-
up (total 12 months). The study included a six-month
treatment period, during which subjects received monthly
intraocular injections of 0.3mg or 0.5mg ranibizumab,
or sham injections; and a six-month observation period,
duringwhichallpatientscouldreceivemonthlyranibizumab
retreatment if they met prespeciﬁed criteria.
Mean change from baseline visual acuity at month six
was +18.3 letters in the 0.5mg ranibizumab group, and
+7.3 letters in the sham group. The percentage of patients
who gained ≥15 letters in visual acuity at month six
were 61.1% in the 0.5mg ranibizumab group, and 28.8%
in the sham group. As in the CRUISE study, the safety
proﬁle of ranibizumab appeared similar to that previous
phase III clinical trials of ranibizumab in other disorders.
Treatment with ranibizumab as needed, during the six-
month observation period, maintained the visual beneﬁts
gained in the initial treatment phase [90].
7. Aﬂibercept
VEGF Trap (aﬂibercept) is a pharmacologically engineered
(fusion) protein that blocks the eﬀects of VEGF by acting
as a decoy receptor [91]. VEGF Trap consists of the ligand-
binding elements of VEGFR1 and VEGFR2, fused to the Fc
(fragmentcrystallizable)portionofhumanimmunoglobulin
G1 (IgG1). VEGF Trap is in commercial development by
Regeneron Pharmaceuticals Inc. (Tarrytown, NY) in the
USA, and by Bayer Healthcare (Leverkusen, Germany) for
global markets. The ocular formulation of VEGF Trap is
knownas“VEGFTrap-Eye”(knowngenericallyasaﬂibercept
ophthalmic solution, and to be marketed as “EYLEA”)—an
iso-osmotic, ultrapuriﬁed formulation for intravitreal injec-
tion. An intravenous formulation is also being developed
for oncological use (this formulation is hyperosmotic and
diluted prior to intravenous infusion) [91].
7.1. Chemistry. VEGF Trap was ﬁrst described in 2002 [92].
Prior to this, the highest potency VEGF blocker consisted
of a soluble decoy receptor created by fusing the ﬁrst three
Ig domains of VEGFR1 to the constant region (Fc portion)
of human IgG1 [91, 93]. This compound demonstrated not
only considerable VEGF binding eﬃcacy but also a number
of unfavorable molecular and pharmacokinetic charac-
teristics (e.g., nonspeciﬁc binding of extracellular matrix
components, and the need for frequent administration at
high concentrations to achieve eﬃcacious levels in rodent8 Journal of Ophthalmology
models). Therefore, in its current construct, VEGF Trap
consists of the second Ig domain of VEGFR1 and the third
Ig domain of VEGFR2, bound to the Fc portion of human
IgG1.
VEGF Trap is produced in Chinese hamster ovary cells
using recombinant techniques, has a protein molecular
weight of 97kDa, and is approximately 15% glycosylated
to yield a total molecular weight of 115kDa (by compari-
son, ranibizumab and bevacizumab have protein molecular
weights of 48kDa and 149kDa, resp.) [91, 94]. VEGF
Trap binds VEGF with higher aﬃnity than monoclonal
antibodies such as bevacizumab; VEGF Trap may, thus, be
active at lower concentrations than other VEGF blocking
drugs and may oﬀer a longer duration between doses when
compared to other drugs. VEGF Trap is also distinguished
from ranibizumab by its ability to bind other VEGF family
members—in particular, placental growth factors 1 and 2
(PLGF1 and PLGF2). Finally, the Fc portion of VEGF Trap
slows clearance by conferring the long-circulating half-life
typically seen with antibodies and, because it contains only
human sequences, its potential for immunogenicity is low
[92].
7.2. Preclinical Studies. The eﬃcacy of VEGF Trap for
the suppression of choroidal neovascularization has been
evaluated in a number of animal models. In mice, sub-
cutaneous injections, or a single intravitreal injection, of
VEGF Trap strongly suppressed choroidal neovasculariza-
tion following laser-induced rupture of Bruch’s membrane
[95]. Subcutaneous injection of VEGF Trap has also been
shown to signiﬁcantly inhibit subretinal neovascularization
intransgenicmicethatexpressVEGFintheirphotoreceptors
[95]. In rats, VEGF Trap has also been found to inhibit CNV
and associated inﬂammation and ﬁbrosis in a subretinal
Matrigel CNV model (Matrigel is a growth factor-reduced,
synthetic matrix that has recently been shown to induce
CNV formation when injected into the subretinal space of
rats)[96].Finally,innonhumanprimates(adultcynomolgus
monkeys), a single intravitreal injection of VEGF Trap has
also been shown to induce inhibition of active CNV leakage
following laser-induced rupture of Bruch’s membrane [94].
The eﬃcacy of VEGF Trap in the prevention of blood-
retinal barrier breakdown has also been assessed in a number
of animal models (i.e., a measure of potential eﬃcacy in
retinal vascular diseases such as diabetic retinopathy and
retinalvenousocclusion)[95].Followinginjectionofrecom-
binant VEGF into the vitreous cavity of mice, VEGF Trap
signiﬁcantly reduced breakdown of the blood-retinal barrier.
Similarly, in transgenic mice where VEGF expression is
induced in the retina, VEGF Trap also reduced breakdown
of the blood retinal barrier.
7.3. Pharmacokinetics and Metabolism. VEGF Trap is cleared
from the circulation through one of two pathways: (1) by
binding to VEGF to form an inactive complex or (2) by
Fc-receptor or pinocytic mediated pathways that culminate
in proteolysis [91]. At low blood levels, the clearance of
VEGF Trap is rapid as a result of binding to VEGF; at very
high circulating doses, VEGF Trap has a terminal half-life
of approximately 17 days. The terminal half-life after human
intravitreal injection is unknown.
7.4. Selected Clinical Studies: Neovascular AMD. The use of
intravitreal VEGF Trap-Eye for the treatment of neovascular
AMD has recently been evaluated in two phase III clinical
trials: the North American VIEW 1 study and the interna-
tional VIEW 2 study (VIEW: “VEGF Trap-Eye: Investigation
of Eﬃcacy and Safety in Wet AMD”). In the VIEW 1 stud-
y, patients receiving VEGF Trap-Eye (2mg), with ﬁxed
monthly retreatment, achieved a signiﬁcantly greater mean
improvement in visual acuity at one year (+10.9 letters)
compared to patients receiving ranibizumab (0.5mg) on a
similarregimen(+8.1letters)(however,allotherdosegroups
of VEGF Trap-Eye in the VIEW 1 study, and all dose groups
in the VIEW 2 study, were not statistically different from
ranibizumab with regard to this endpoint). Of note, subjects
receiving VEGF Trap-Eye (2mg)—every two months—
gained, on average, 7.9 letters in VIEW 1 and 8.9 letters
in VIEW 2 (http://www.regeneron.com/ accessed August 31,
2011).
7.5. Selected Clinical Studies: CRVO. The use of intravitreal
VEGF Trap-Eye for the treatment of central retinal vein
occlusion (CRVO) has recently been evaluated in two
phase III clinical trials: COPERNICUS (Controlled Phase 3
Evaluation of Repeated intravitreal administration of VEGF
Trap-Eye in Central retinal vein occlusion) and GALILEO
(General Assessment Limiting Inﬁltration of Exudates in
central retinal vein Occlusion with VEGF Trap-Eye). On
December 20, 2010, the results of the COPERNICUS study
were announced. In this trial, 56.1% of patients receiving
monthly VEGF Trap-Eye (2mg) gained at least 15 letters
of visual acuity, versus 12.3% of controls. Furthermore, the
mean change in visual acuity, from baseline, was +17.3
letters versus −4.0 letters for the sham injection group
(http://www.regeneron.com/ accessed August 31, 2011).
8. Conclusions andFutureDirections
A number of points from this review, with signiﬁcant clinical
implications, are worth highlighting. In terms of vascular
development, coverage of new vessels by pericytes appears
to be a key event resulting in loss of VEGF dependence;
awareness of this ﬁnding is important for clinicians as
the role of anti-VEGF therapies continues to expand, both
within the posterior segment and elsewhere in the eye (e.g.,
treatment of corneal neovascularization). The development
of imaging modalities capable of assessing this cell type, and
applicableinaclinicalsetting,isthusofconsiderableinterest.
In terms of drug development and molecular charac-
teristics, a number of important ﬁndings emerge. Firstly,
the aptamer pegaptanib, while oﬀering low immunogenicity,
excellent safety proﬁles, and the prospect of selective VEGF
inhibition, does not provide the extent of VEGF blockade
necessary for optimal clinical outcomes in a variety of ocular
diseases. Secondly, the antibody fragment ranibizumab, by
blocking all VEGF isoforms, has proven eﬀective in large
clinical trials for a variety of ocular diseases (neovascularJournal of Ophthalmology 9
AMD, DME, RVO), with a good systemic safety proﬁle, but
at a high cost. Conversely, bevacizumab, a full-length anti-
body, oﬀers a low-cost alternative to ranibizumab that has
recently been validated in large clinical trials. However, some
concerns regarding its use include (1) the longer systemic
half-life of a full-length antibody, with the potential for
increased systemic adverse events, (2) the potential for the Fc
component of a full-length antibody to trigger inﬂammatory
processes, (3) the need for precise compounding of the drug
for intraocular administration, and (4) the decreased aﬃnity
of bevacizumab for VEGF relative to that of ranibizumab.
Nonetheless, the experience of retinal specialists worldwide
attests to the profound beneﬁts that patients have received
following intravitreal bevacizumab therapy. Finally, VEGF
Trap appears to have a higher VEGF binding aﬃnity
than bevacizumab and, unlike ranibizumab, can bind other
members of the VEGF family (e.g., PLGF). VEGF Trap may,
thus, oﬀer a longer duration between doses when compared
to ranibizumab and bevacizumab.
8.1. Future Directions. The introduction of anti-VEGF ther-
apies represented a signiﬁcant milestone in the medical
treatment of retinal diseases. Progress in this area continues
to be made at a rapid pace, with the optimization of treat-
ment dosages (e.g., increased dosages of ranibizumab in the
ongoing HARBOR trial) and schedules (e.g., PrONTO and
CATT studies) and with the development of new agents
aimed at anti-VEGF blockage (e.g., siRNAs) [82, 97, 98]. Use
of combination therapies may also provide synergistic ben-
eﬁts including better visual outcomes, reduced frequency of
treatments, lower risk of adverse events, and decreased like-
lihood of “escape” (i.e., the development of alternative path-
ways by which cells allow themselves to overcome iatrogenic
inhibition) [99, 100]. Already, combination approaches have
been examined in neovascular AMD (e.g., anti-VEGF ther-
apy in combination with verteporﬁn photodynamic ther-
apy or macular radiation) and in DME (e.g., anti-VEGF
therapy followed by macular laser photocoagulation). In
the future however, greater visual gains may require more
novel strategies aimed at promotion of RPE and pho-
toreceptor survival. In this regard, a number of therapies
using neuroprotective, anti-inﬂammatory, and visual-cycle
targeted strategies are in development, for AMD and for
other disorders [101].
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